Menu
← Oncology Approval Tracker
FDA DECISION ·
Zegfrovy
sunvozertinib · Dizal (Jiangsu) Pharmaceutical
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion by an FDA-approved test, after progression on or after platinum chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The oral EGFR inhibitor provides a targeted option after platinum for exon 20 insertion disease.
What research teams should watch
Make the exact exon 20 alteration and prior platinum exposure visible in screening records, and prepare counseling on rash and diarrhea.
PRIMARY RECORDS